Chamanza Ronnie, Darville Nicolas, van Heerden Marjolein, De Jonghe Sandra
1 Preclinical Development and Safety, Janssen Research & Development, Janssen Pharmaceutical Companies of Johnson and Johnson, Beerse, Belgium.
Authors contributed equally to the manuscript.
Toxicol Pathol. 2018 Jan;46(1):85-100. doi: 10.1177/0192623317737295. Epub 2017 Nov 2.
To investigate the effects of common nanosuspension-stabilizing excipients on the nature and temporal evolution of histopathological changes at intramuscular (i.m.) administration sites, 5 groups of 39 male rats per group received a single injection of 1 of the 5 analogous crystalline drug nanosuspensions containing 200 mg/ml of an antiviral compound with particle sizes of ±200 nm and identical vehicle compositions, except for the type of nanosuspension stabilizer. The investigated stabilizers were poloxamer 338, poloxamer 407, d-α-tocopherol polyethylene glycol 1,000-succinate (TPGS), polysorbate 80, and polysorbate 80 combined with egg phosphatidylglycerol. Histopathology and immunohistochemistry revealed progressive inflammatory changes at the i.m. administration sites and the draining lymph nodes that differed according to the time point of sacrifice and the type of stabilizer. Although the overall time course of inflammatory changes was similar across the groups, differences in the nature, severity, and timing of the inflammatory response were observed between animals injected with poloxamer- or TPGS-containing nanosuspensions and those injected with formulations containing polysorbate 80. A more severe and prolonged active inflammatory phase, the presence of multinucleate giant cells, prolonged macrophage infiltration of the formulation depot, and more persistent histiocytic infiltrates in the lymph nodes were observed in the polysorbate 80-containing nanosuspension groups. Such vehicle-mediated effects could influence the overall tolerability profile of long-acting nanosuspensions.
为研究常用纳米混悬液稳定剂对肌内注射部位组织病理学变化的性质和时间演变的影响,每组39只雄性大鼠,共5组,分别单次注射5种类似的结晶药物纳米混悬液中的1种,这些纳米混悬液含有200 mg/ml的抗病毒化合物,粒径约为200 nm,除纳米混悬液稳定剂类型外,载体成分相同。所研究的稳定剂为泊洛沙姆338、泊洛沙姆407、d-α-生育酚聚乙二醇1000琥珀酸酯(TPGS)、聚山梨酯80以及聚山梨酯80与蛋黄磷脂酰甘油的组合。组织病理学和免疫组织化学显示,肌内注射部位和引流淋巴结出现进行性炎症变化,这些变化因处死时间点和稳定剂类型而异。尽管各组炎症变化的总体时间进程相似,但在注射含泊洛沙姆或TPGS的纳米混悬液的动物与注射含聚山梨酯80制剂的动物之间,观察到炎症反应在性质、严重程度和时间上存在差异。在含聚山梨酯80的纳米混悬液组中,观察到更严重、持续时间更长的活跃炎症期、多核巨细胞的存在、制剂储存部位巨噬细胞浸润延长以及淋巴结中组织细胞浸润更持久。这种载体介导的效应可能会影响长效纳米混悬液的总体耐受性。